3,275 Shares in Astrazeneca Plc $AZN Acquired by Wealth Management Associates Inc.

Wealth Management Associates Inc. bought a new position in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,275 shares of the company’s stock, valued at approximately $301,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of Montreal Can boosted its stake in Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Fayez Sarofim & Co increased its stake in Astrazeneca by 173.4% in the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after purchasing an additional 2,376,032 shares in the last quarter. Holocene Advisors LP raised its holdings in shares of Astrazeneca by 41.8% during the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the period. Raymond James Financial Inc. boosted its position in shares of Astrazeneca by 64.8% during the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after purchasing an additional 1,487,662 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HSBC reaffirmed a “buy” rating and set a $108.00 price target on shares of Astrazeneca in a research note on Wednesday, December 10th. Citigroup began coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Barclays restated an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Weiss Ratings began coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Price Performance

AZN opened at $203.32 on Friday. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The stock has a market cap of $315.33 billion, a P/E ratio of 31.04, a PEG ratio of 1.51 and a beta of 0.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s payout ratio is currently 66.26%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.